ARCEDI Biotech is pioneering advancements in prenatal diagnostics through its innovative approach to non-invasive prenatal testing (NIPT). The company focuses on cell-free non-invasive prenatal testing (cfNIPT) and has developed a unique technology that isolates fetal cells from maternal blood for genetic analysis. This method aims to replace traditional invasive procedures such as chorionic villus sampling (CVS) and amniocentesis, providing a safer alternative for expectant parents. ARCEDI's flagship products, the EVITA TEST COMPLETE and EVITA TEST GENDER, offer comprehensive genome-wide analysis of the fetus, allowing for early detection of genetic conditions without the risks associated with invasive testing.

In addition to its core testing technologies, ARCEDI Biotech has a robust intellectual property portfolio, with several patents protecting its methodologies and innovations until 2031. The company’s research includes studies on the clinical applications of cell-based NIPT for diagnosing monogenic disorders and assessing fetal health. By utilizing circulating fetal cells, ARCEDI's tests can accurately identify various genetic disorders, including autosomal dominant, autosomal recessive, and X-linked conditions. This cutting-edge technology not only enhances the safety and accuracy of prenatal diagnostics but also contributes to ongoing research in identifying biomarkers for conditions such as preterm prelabor rupture of membranes.

Denmark

ARCEDI Biotech ApS is a Danish biotech company involved in developing technologies for rare cell detection, a widely sought after application in the prenatal as well as cancer diagnostics.

ARCEDI Biotech has proprietary method to enrich fetal cells from circulating maternal blood with high efficiency. Once enriched, the fetal cells can be utilized for downstream analysis using technologies such as FISH, 'Next Generation Sequencing', etc.

ARCEDI Biotech

Company Details